Keyphrases
Type 2 Diabetic Patients
100%
Glucagon-like
100%
Liraglutide
100%
Receptor Agonist
100%
Glycemic Control
100%
Agonist Treatment
100%
A1 Receptor
100%
Placebo
85%
HbA1c Levels
28%
Training Session
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Maximal Oxygen Uptake
14%
Robust Weights
14%
Obese Patients
14%
Weight Loss
14%
Body Fat
14%
Quality of Life
14%
Resistance Training
14%
Type 2 Diabetes Prevention
14%
Mean Standard Deviation
14%
Fasting Plasma Glucose
14%
Systolic Blood Pressure
14%
Dysregulated
14%
Glycated Hemoglobin A1c
14%
Exercise Effect
14%
Placebo Groups
14%
Medicine and Dentistry
Liraglutide
100%
Patient with Type 2 Diabetes
100%
Glycemic Control
100%
Glucagon-Like Peptide-1 Agonist
100%
Placebo
100%
Maturity Onset Diabetes of the Young
28%
Hemoglobin A1c
28%
Body Fat
14%
Obesity
14%
Quality of Life
14%
Systolic Blood Pressure
14%
Oxygen Consumption
14%
Resistance Training
14%
Sedentary Patient
14%
Glycated Hemoglobin
14%
Body Weight
14%
Nursing and Health Professions
Glucagon Like Peptide 1 Receptor Agonist
100%
Liraglutide
100%
Patient with Type 2 Diabetes
100%
Placebo
100%
Hemoglobin A1c
28%
Non Insulin Dependent Diabetes Mellitus
28%
Body Fat
14%
Glycosylated Hemoglobin
14%
Obesity
14%
Systolic Blood Pressure
14%
Body Weight
14%
Sedentary Patient
14%
Glucose Blood Level
14%
Quality of Life
14%
Immunology and Microbiology
Glycemic Control
100%
Glucagon-Like Peptide-1
100%
Agonist
100%
Glucose Blood Level
25%
Oxygen Consumption
25%
Systolic Blood Pressure
25%
Body Fat
25%
Resistance Training
25%
Glycosylated Hemoglobin
25%
Body Weight
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Placebo
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Non Insulin Dependent Diabetes Mellitus
100%
Hemoglobin A1c
28%
Glycosylated Hemoglobin
14%
Obesity
14%